The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

After adjusting for the weight loss benefits of surgery, GLP-1 drugs were linked to a 41% lower risk of obesity-related ...

GLP-1 agonists, medications commonly used for weight loss and type 2 diabetes, may also help reduce alcohol intake — an ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being ...